Professor David Allsop’s research group, following extensive years of research have recently developed a novel retro-inverted peptide-based amyloid beta aggregation inhibitor that may be useful for treatment of Alzheimer’s disease. Tau aggregation inhibitors are a completely new venture for this research group. For my novel PhD research I am pioneering and developing peptide-based tau aggregation inhibitors, testing their interactions with a variety of tau protein aggregation systems and characterising subsequent structures formed from co-incubation. My successful lead tau aggregation inhibitor may be useful as a potential treatment for Alzheimer's disease and perhaps other tauopathies.